Evidence strength for the context described on this page.
PEPTIDE ATLAS / IMMUNE & GUT / KPV
Not FDA-approvedPreclinical
KPV
ALSO KNOWN ASLys-Pro-Val · alpha-MSH fragment
A three-amino-acid anti-inflammatory fragment marketed for gut and skin health without human exposure data.
01CATEGORYImmune & gut
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEMarketed as oral, topical, nasal or injectable products; none is approved
04DOSE BASISReported clinic/community use only
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What KPV is.
A short C-terminal fragment of alpha-melanocyte-stimulating hormone studied in inflammatory and barrier models.
HOW IT IS THOUGHT TO WORK
Proposed to reduce pro-inflammatory signaling and influence epithelial or immune responses in preclinical models.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Preclinical anti-inflammatory signals
- No established human gut, skin or wound-healing benefit
- Treatment of inflammatory bowel disease
- Leaky-gut repair
- Wound healing
- Safe oral, topical or injectable dosing
Evidence grade: Preclinical. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Reported clinic/community use onlyMost commonly reported clinic/community range: 200–500 mcg once daily orally or subcutaneously for 4–8 weeks; some oral protocols use 500 mcg–1 mg/day. FDA has identified no human exposure data for KPV drug products, so these are market-use ranges based largely on preclinical rationale—not approved or evidence-based human doses.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- Commonly reported once daily for 4–8 weeks; topical concentrations and nasal schedules vary widely.
- How to interpret it
- FDA reports no identified human exposure data. Oral, topical and injectable amounts are not interchangeable, and preclinical PepT1 transport findings do not establish clinical efficacy or a safe oral dose.
- Route
- Marketed as oral, topical, nasal or injectable products; none is approved
- Duration
- Reported cycles: 4–8 weeks; no established course
- Men & women
- No human dose or sex-specific safety data; the same reported range is usually used for men and women without validation.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- GI symptoms with blood, weight loss or anemia require clinical evaluation
- No commercial inflammation panel validates KPV use
SAFETY
Risks, red flags and reasons to avoid it.
- Unknown human toxicity
- Product identity, purity and sterility risk
- Potential immunogenicity depending on route
- Delayed diagnosis of inflammatory disease
- Human use outside research
- Self-treatment of inflammatory bowel disease
- Pregnancy
- Injection
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Research-chemical and some compounded marketing; not FDA-approved.
A peptide can be extremely short and still have uncertain pharmacology, manufacturing quality and human safety.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP